drugset / Trial / NCT07579429
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicotinamide riboside and pterostilbene at different doses. The primary goals of the study are: * to assess if study drug improves cytopenias in patients * to determine safety of the study drug in patients
Timeline
- Start
- 2026-05-20
- Primary completion
- 2029-12-18
- Completion
- 2030-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nicotinamide riboside | Small molecule | 250 mg | Oral |
| Subject | Pterostilbene | Small molecule | 50 mg | Oral |